H.C. Wainwright analyst Debjit Chattopadhyay maintained a Buy rating on Jounce Therapeutics Inc (JNCE) today and set a price target of $13. The company’s shares opened today at $4.08.
Chattopadhyay commented:
“We anticipate Jounce exiting 2019 with approximately $167M in cash, which should be sufficient to fund operations into 2021, by our estimates. While the readout from the EMERGE study, elaborated upon subsequently, is about a year out, the study remains significantly divergent from traditional I/O combination studies, with its focus on the emergence of pharmacodynamic biomarker upon stimulation with an anti-CTLA-4 and its correlation to likely durable responses on subsequent agonism with an ICOS agonist. We realize it is easier to be wise after the event, and given the MOA and the likely synergy between CTLA-4 inhibition and ICOS agnoism, the EMERGE study should have preceeded the ICONIC program. However, ICONIC is now water under the bridge, and a range of learnings have been incorporated into the EMERGE program.”
According to TipRanks.com, Chattopadhyay has 0 stars on 0-5 star ranking scale with an average return of -3.2% and a 39.5% success rate. Chattopadhyay covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Precision BioSciences Inc, and Voyager Therapeutics Inc.
Jounce Therapeutics Inc has an analyst consensus of Hold, with a price target consensus of $13.
See today’s analyst top recommended stocks >>
The company has a one-year high of $8.58 and a one-year low of $2.66. Currently, Jounce Therapeutics Inc has an average volume of 179.2K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Jounce Therapeutics, Inc. is a clinical stage immunotherapy company, which treat cancer by developing therapies that enable the immune system to attack tumors and provide long-lasting benefits to patients. Its products pipeline include JTX-2011 (ICOS); JTX-4014 (PD-1); Lead Macrophage Program; Macrophage Targeting; T Reg; B Cells; and Stromal Targeting.
